Follows the Society's strong endorsement of
EsoGuard medical policy coverage by payors
NEW
YORK, Sept. 24, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company") a commercial-stage, cancer prevention medical
diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
announced that the American Foregut Society's (AFS) 2024 Annual
Meeting, being held from September 26-28,
2024 at the Gaylord Rockies Resort & Convention Center
in Aurora, CO, will be
highlighting its EsoGuard® Esophageal DNA Test for
early detection of esophageal precancer to conference
participants.
During the meeting, Dan Lister,
M.D., current President-elect and one of the co-founders of the
AFS, will lead a session titled "Finding Barrett's - Time to
Ditch the Scope?" where he will discuss the value and utility
of EsoGuard as a highly effective non-invasive alternative to
screening upper endoscopy (EGD) for detecting esophageal precancer
(Barrett's Esophagus or BE). This session follows the AFS's recent
open letter, which highlights the critical need for early detection
of esophageal precancer to prevent highly lethal esophageal cancer
and strongly advocates for medical policy coverage of EsoGuard by
commercial payors. The letter emphasizes the strong scientific
evidence supporting the use of EsoGuard as a minimally invasive
alternative to screening EGD and its incorporation in the practices
of AFS physicians. Dr. Lister's session will explore how EsoGuard
serves as a powerful tool to triage at-risk patients, thus enabling
more efficient use of endoscopy resources while enabling effective
early detection of esophageal precancer and facilitating
surveillance and treatment to prevent progression to cancer.
"We are honored to once again participate in the AFS Annual
Meeting, especially following their recent strong endorsement of
EsoGuard," said Lishan Aklog, M.D.,
Lucid's Chairman and Chief Executive Officer. "We are grateful to
the AFS and its leaders, including Dr. Lister, for their vocal
advocacy in support of esophageal precancer testing to prevent
esophageal cancer, and the critical role EsoGuard is playing as the
first and only commercially available non-endoscopic biomarker test
designed to do so. We have been proud to support the AFS since its
inception and appreciate their efforts at the vanguard of
esophageal health and cancer prevention."
The AFS Annual Meeting is a premier event that brings together
gastroenterologists and surgeons to collaborate on personalizing
treatment and improving patient outcomes for foregut diseases. The
conference covers a wide range of topics, including diagnostics,
novel therapies, and the latest advancements in foregut health.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company and
subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the
millions of patients with gastroesophageal reflux disease (GERD),
also known as chronic heartburn, who are at risk of developing
esophageal precancer and cancer. Lucid's EsoGuard®
Esophageal DNA Test, performed on samples collected in a brief,
noninvasive office procedure with its EsoCheck®
Esophageal Cell Collection Device, represent the first and only
commercially available tools designed with the goal of preventing
cancer and cancer deaths through widespread, early detection of
esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com
and for more information about its parent company PAVmed, please
visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of Lucid's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance Lucid's products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid's clinical and
preclinical studies; whether and when Lucid's products are cleared
by regulatory authorities; market acceptance of Lucid's products
once cleared and commercialized; Lucid's ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid continues to monitor the COVID-19 pandemic and
the pandemic's impact on Lucid's businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond Lucid's control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect Lucid's future operations, see Part
I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, "Risk Factors" in any
Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its
most recent Annual Report. Lucid disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/american-foregut-societys-2024-annual-meeting-to-highlight-lucid-diagnostics-esoguard-esophageal-precancer-test-302256688.html
SOURCE Lucid Diagnostics
